Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 197-209 , May 2005

Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours

References 

  1. Aareleid T, Sant M, Hédelin G. Improved survival for patients with testicular cancer in Europe since 1978. Eurocare Working Group. Eur J Cancer. 1998;34(14):2236–2240
  2. Feuer EJ, Frey CM, Brawley OW, et al. After a treatment breakthrough:a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol. 1994;12(2):368–377
  3. Bosel GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337(4):242–253
  4. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594–603
  5. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer. 2001;191(7):1304–1315
  6. Horwich A, Mason M, Hendry W. Testicular tumours. In: 2nd ed..  Souhami R,  Tannock I,  Hohenberger P,  Horiot JC editor. Oxford textbook of oncology. vol. 2:New York: Oxford University Press; 2002;p. 2007–2033
  7. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440
  8. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J Clin Oncol. 1998;16(7):2500–2504
  9. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559–2563
  10. Harstrick A, Schmoll HJ, Wilke H, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol. 1991;9(9):1549–1555
  11. Ghosn M, Droz JP, Theodore C, et al. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen. Cancer. 1988;162(1):24–27
  12. Bokemeyer C, Hartmann JT, Kuczyk MA, et al. Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol. 1998;16(2):155–162
  13. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol. 1996;7(1):31–34
  14. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18(12):2413–2418
  15. Kawai K, Miyazaki J, Tsukamoto S, et al. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. Jpn J Clin Oncol. 2003;33(3):127–131
  16. Bokemeyer C, Gerl A, Schoffski P, et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol. 1999;17(2):512–516
  17. Einhorn LH, Stender MJ, William SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol. 1999;17(2):509–511
  18. Hinton S, Catalano P, Einhorn L, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002;20(7):1859–1863
  19. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002;20(8):2031–2037
  20. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;122(1):108–114
  21. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004;15(3):493–497
  22. DeWys WD, Begg C, Slayton R, et al. Chemotherapy for advanced germinal cell neoplasms: preliminary report of an Eastern Cooperative Oncology Group Study. Cancer Treat Rep. 1979;63(9–10):1675–1680
  23. Samson MK, Rivkin SE, Jones SE, et al. Dose–response and dose–survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southern Oncology Group Study. Cancer. 1984;3(3):1029–1035
  24. Ozols RF, Ihde DC, Linehan WM, et al. A randomised trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminatous germ-cell tumors. J Clin Oncol. 1988;6(6):1031–1040
  25. Nichols CR, William SD, Loehrer PJ, et al. Randomised study of cisplatin dose intensity in poor-risk germ cell tumours: a South-eastern Cancer study group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9(7):1163–1172
  26. Bokemeyer C, Harstrick A, Beyer J, et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ-cell tumors. Semin Oncol. 1998;25(2 Suppl. 4):24–32
  27. Wettlaufer JN, Feiner AS, Robinson WA. Vincristine, cisplatin and bleomycin with surgery in the management of advanced metastatic non-seminatous testis tumors. Cancer. 1984;53(2):203–209
  28. Horwich A, Brada M, Nicholls J, et al. Intensive induction chemotherapy for poor-risk non-seminomatous germ-cell tumours. Eur J Cancer Clin Oncol. 1989;25(2):177–184
  29. Horwich A, Dearnaley DP, Norman A, et al. Accelerated chemotherapy for poor prognosis germ-cell tumours. Eur J Cancer. 1994;30A(11):1606–1611
  30. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998;16(2):692–701
  31. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7(7):932–939
  32. Droz JP, Pico JL, Ghosn M, et al. Long term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory Germ cell cancer. Eur J Cancer. 1991;27(7):831–835
  33. Broun ER, Nichols CR, Einhorn LH, Tricot GJ. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary non-seminomatous mediastinal germ cell tumours. Cancer. 1991;68(7):1513–1515
  34. Broun ER, Nichols CR, Tricot G, et al. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumours. Bone Marrow Transpl. 1991;7(1):53–56
  35. Rosti G, Albertazzi L, Salvioni R, et al. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ-cell tumors: a phase two study. Ann Oncol. 1992;3(10):809–812
  36. Nichols CR, Andersen J, Lazrus HM, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Co-operative Oncology Group protocol. J Clin Oncol. 1992;10(4):558–563
  37. Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Co-operative Study Group. J Clin Oncol. 1994;12(6):1223–1231
  38. Flechon A, Biron P, Droz JP. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience. Int J Cancer. 1999;83(6):844–847
  39. Kellner A, Grothey C, Rie H, Schmoll J. Sequential high-dose chemotherapy with paclitaxel, ifosfamide, carboplatin and etoposide (HD P-ICE) for platinum refractory and multiple relapsed germ cell cancer (GCC). Results of a phase II study. Proc Am Cancer Soc. 2003;1774:442
  40. Ibrahim A, Zambon E, Bourhis JH, et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients: a pilot study. Eur J Cancer. 1993;29A(10):1398–1403
  41. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ-cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol. 1996;14(4):1098–1105
  42. Barnett MJ, Coppin CM, Murray N, et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ-cell tumours. Br J Cancer. 1993;68(3):594–598
  43. Margolin BK, Doroshow JH, Ahn C, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol. 1996;14(10):2631–2637
  44. Broun ER, Nichols CR, Gize G, et al. Tandom high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer. 1997;79(8):1605–1610
  45. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000;18(19):3346–3351
  46. Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001;19(1):81–88
  47. Rosti G, Pico J-L, Wandt H, et al. High-dose chemotherapy (hdc) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94. Proc Ann Meet Am Soc Clin Oncol. 2002;716:
  48. Beyer J. High dose versus conventional dose first salvage treatment in nonseminoma;a matched pair analysis. Proc Ann Meet Am Soc Clin Oncol. 1999;1255:
  49. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ-cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14(10):2638–2645
  50. Droz JP, Pico JL, Ghosn M, et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non-seminomatous germ-cell tumors. Bull Du Cancer. 1992;79(5):497–507
  51. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor-risk of non-seminomatous germ-cell tumours Preliminary results of a French randomised trial. Eur Urol. 1993;23(1):213–217
  52. Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ-cell tumors. J Natl Cancer Inst. 1993;85(22):1828–1835
  53. Morris MJ, Bosl GJ. High dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering Experience (1988–1999). Int J Cancer. 1999;83(6):834–838
  54. Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21(22):4083–4091

PII: S0305-7372(05)00029-0

doi: 10.1016/j.ctrv.2005.02.001

Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 197-209 , May 2005

Article Tools